ArticleGland surgery2026
Impact of postoperative hyperamylasemia and post-pancreatectomy acute pancreatitis following pancreaticoduodenectomy in a single-center cohort.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical significance of postoperative hyperamylasemia (POH) and post-pancreatectomy acute pancreatitis (PPAP) following pancreaticoduodenectomy (PD) is understudied. Hence, we aimed to determine the incidence, risk factors, and short-term clinical impact of post-PD POH and PPAP. Methods: A retrospective, single-center, observational study was conducted with consecutive adult patients who underwent surgery between January 2012 and September 2025. POH and PPAP were defined and graded using the 2022 International Study Group of Pancreatic Surgery (ISGPS) consensus criteria. Results: Among the 244 participants, 25.4% developed POH and 31.1% developed PPAP. Those with PPAP demonstrated significantly higher rates of clinically relevant postoperative pancreatic fistula (CR-POPF), postoperative complications (Clavien-Dindo classification ≥3), and longer hospital and intensive care unit (ICU) stays compared to those without PPAP. There was no difference in the 90-day mortality rate. Perioperative factors were significantly associated with PPAP in the univariate analysis, including male sex [odds ratio (OR) =1.83; 95% confidence interval (CI): 1.05-3.17; P=0.03] and the presence of preoperative biliary drainage (OR =1.84; 95% CI: 1.01-3.35; P=0.047). Two intraoperative characteristics were identified as significant risk factors for PPAP: soft pancreatic texture (OR =2.58; 95% CI: 1.39-4.81; P=0.003) and a narrower pancreatic duct (OR =0.77; 95% CI: 0.66-0.99; P=0.002). CR-POPF was associated with an increased incidence of PPAP (OR =11.13; 95% CI: 5.61-22.07; P=0.001). In the multivariate analysis, male sex (OR =2.49; 95% CI: 1.13-5.51; P=0.02) and CR-POPF (OR =17.55; 95% CI: 7.13-43.19; P<0.001) were identified as risk factors for PPAP. Conclusions: PPAP is associated with an increased risk of adverse outcomes. It has potential as an indicator of surgical morbidity and of prolonged hospital and ICU stays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.